Stop the Progression of Dry AMD.
Understanding Dry AMD
Dry AMD (dAMD) is the 'atrophic' or non-exudative form of macular degeneration. Unlike the Wet form, it progresses slowly, characterised by the thinning of the macula the part of the retina responsible for your central vision.
While it rarely causes total blindness, the loss of central vision can be devastating for reading, driving, and recognising faces. Until recently, patients were told 'nothing can be done.' Our clinic exists to change that narrative.
Expert Care Led by Sarah Farrant
Sarah Farrant is a nationally recognized expert in ocular surface disease and dry eye management. As one of the few optometrists in the UK with Independent Prescribing rights, she brings a medical level of care to the Dry AMD Clinic.
BCLA President
British Contact Lens Association
TFOS Ambassador
Tear Film & Ocular Surface Society
Therapeutics Specialist
Independent Prescriber
National Speaker
Keynote lecturer on Dry Eye
Learn More About Your Treatment
Watch our short educational videos to understand the science behind Photobiomodulation and what you can expect during your visit.
Introduction to Dry AMD
Sarah Farrant explains the mechanics of Dry AMD and why early intervention is crucial to preserving vision.
How Photobiomodulation Works
Discover the science of light therapy and how it revitalises retinal cells at a mitochondrial level.
Treatment Demonstration
See what happens during a typical session using the advanced Eye-light mask system.
Comparison: Valeda Light Delivery System vs. Eye-light®
For patients researching their options, this table compares the two primary PBM technologies available in the UK.
| Feature | Valeda (LumiThera) | Eye-light® (Espansione) |
|---|---|---|
| Technology | Photobiomodulation (PBM) | Photobiomodulation (PBM) + LLLT |
| Delivery Method | Desktop Device (Patient sits in front) | Wearable Mask (Sits directly on face) |
| Light Wavelengths | Yellow, Red, Near-Infrared | Yellow, Red, Near-Infrared |
| Primary Target | Retina (Macula) | Retina + Peri-orbital Area (Eyelids/Glands) |
| Comfort Level | Non-invasive, requires fixation | Non-invasive, fully relaxed (Reclined) |
| Additional Benefits | Focuses strictly on AMD | Treats Dry Eye & MGD concurrently |
A breakthrough approach to Dry AMD management.
Utilising light energy-based technology that stimulates cellular repair and regeneration, PBM from DryAMD Clinic is at the forefront of macular degeneration treatment.
Your Treatment Journey
A clear path to preserving your vision.
Book Consultation
Secure your baseline assessment appointment online or by phone
Initial Cycle
Attend 8 sessions over 3-4 weeks. Includes full imaging and vision checks.
Join Eye Plan
Switch to the £200/mo plan to cover future maintenance cycles.
Maintenance
Return every 4-6 months for a 6 session top up to preserve results.
The DryAMD Clinic Difference
At DryAMD Clinic, we know how important preserving your vision is. We work with you throughout your treatment to achieve the best results, from taking a baseline assessment to moving onto consistent maintenance cycles
Our PBM treatment is proven to help slow the progress of macular degeneration, giving you a better chance of maintaining your eyesight for longer. Your vision matters — let us help you protect it for the years ahead.
Get in touch with us today to discover more about our PBM treatment and start your journey.
Dry AMD Treatment FAQs
Common questions about our photobiomodulation therapy.
Can Dry AMD Be Stopped Completely?
Unfortunately, there is no way to completely halt the progression of dry AMD. However, dry AMD treatment that utilises photobiomodulation can significantly slow the progress of degeneration, preserving eyesight as much as possible.
How Often Should I Have Dry AMD Treatments?
Initial treatment involves 8 sessions spaced 3-4 days apart. After 4-6 months, a maintenance cycle is recommended consisting of 6 sessions.
Can You Lose Your Sight With Dry Macular Degeneration?
Dry AMD affects central vision, which is vital for reading and recognizing faces. While it rarely causes total blindness (peripheral vision usually remains), unmanaged progression can severely impact your quality of life.
Can Dry Macular Degeneration Turn Into Wet?
Yes, in some cases Dry AMD can progress to Wet AMD. However, the Yellow Light therapy we use specifically inhibits VEGF, a protein linked to the development of Wet AMD, potentially reducing this risk.
LightWave I Study Highlights Benefits of PBM Therapy in Dry AMD at 12 Months.
Anatomical Outcomes: Mean drusen volume (MDV) decreased significantly in the PBM group (-0.03 ± 0.05 mm³), while it increased in the sham group over the 12-month period.
Functional Outcomes: Best Corrected Visual Acuity (BCVA) improved by +1.31 letters in the PBM group, compared with a decline of -2.7 letters in the sham group.
Safety Profile: The PBM treatment was highly tolerated with no evidence of phototoxicity or treatment-related conversion to wet AMD.
'The combination of statistically significant anatomical and functional benefits, along with a favorable safety profile, positions PBM as a promising therapeutic option for early-intermediate dry AMD, for which no approved disease-modifying treatments currently exist.' — Dr. Claudio Iovino, LightWave I Investigator